Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheum with a View

Richard S. Panush, MD  |  Issue: July 2011  |  July 12, 2011

Richard S. Panush, MD

PERRLA

How many times do we write this or see this recorded or presented without really carefully examining the eye or the fundus? How many of us still look at the fundus? Most medical residents don’t even carry or own ophthalmoscopes and have little comfort with the exam of the eye or fundus. This leads me to the new recommendations regarding antimalarials. Recently, my college and medical school roommate, Marty Pearlman, MD, and his wife visited my wife and me. Marty went into ophthalmology and now does retinal surgery in Lansing, Michigan. Marty’s love for what he does is so infectious that two of his four children are also ophthalmologists; in fact, one of them specializes in the retina.

During our visit, Marty informed me that the American Academy of Ophthalmology (AAO) developed a new set of recommendations on screening for antimalarials.1 I was unaware of this—and perhaps others are, too. Briefly, these are revisions of 2002 recommendations. This update was prompted by improved screening tools and data, suggesting that risk of drug toxicity increases toward 1% after five to seven years of use or a cumulative dose of 1,000 grams of hydroxychloroquine.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Recommendations are that a routine dosage of 400 mg hydroxychloroquine daily is acceptable for all, but for individuals of short stature (rather than dosing by weight), baseline evaluation should be carried out, annual screening should begin after five years unless there are unusual risks, and at least one of the newer tests—multifocal electroretinogram (mfERG), spectral domain optical coherence tomography, or fundus autofluorescence—should be used routinely. Additionally, mfERG may replace the visual field exam, Amsler grid testing is no longer needed, and fundus exams should be documented. (Editor’s Note: For more on the new AAO guidelines, see “Hydroxychloroquine Retinopathy Still Alive and Well” in the May 2011 issue of The Rheumatologist, p. 50, or online at www.the-rheumatologist.org/details/article/1066217/.html.)

Marty has done very well, and I couldn’t be happier for his success. I recall when I moved out of our shared apartment (I was getting married) that Marty and I had to split our stuff, most of which had little value. I lost the final coin flip, so he got the good rug, and I was left with the stethoscopic heart sounds record. So, he still owes me; maybe he can show me how to do some of those retinal tests.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
What is contained in a tear?
What is contained in a tear?

There Will Never Be a Panush’s Syndrome

Nor will there be a Panush’s disease, or even Panush’s sign. My mom (may she rest in peace) would have been disappointed. We all were notified electronically about the recommendations of the ACR, the American Society of Nephrology, and European League Against Rheumatism to begin shifting away from eponyms.2 This was prompted “by evidence that Dr. Friedrich Wegener was a member of the Nazi party before and during World War II,” according to the authors of the article, which was published in Arthritis & Rheumatism, Dr. Wegener may also have been complicit with war crimes.

Page: 1 2 3 | Single Page
Share: 

Filed under:Practice SupportProfiles Tagged with:HYDROXYCHLOROQUINEpatient carePractice ManagementretinarheumatologistTreatment

Related Articles

    Ocular Disease Monitoring Critical to Avoid Retinal Toxicity from Hydroxychloroquine

    November 16, 2016

    Both due to its efficacy and favorable side effect profile when compared with alternative drugs for rheumatologic conditions, hydroxychloroquine is an important agent in rheumatologists’ armamentarium. However, one barrier to hydroxychloroquine use can be its effects on the eye (also see “Revised Retinopathy Screening Guidelines,”). Ocular side effects of hydroxychloroquine can include impact on the…

    The Granulomatosis of Wegener’s

    May 16, 2011

    Delving deeper into the nonvasculitis aspects of the disease

    Watch Those Eyes

    December 1, 2007

    What you need to know about Uveitis in Rheumatic Diseases

    An Overview of Pediatric, Noninfectious Uveitis

    October 18, 2018

    Uveitis is an inflammation of the uvea, which comprises the iris, ciliary body and choroid. Uveitis can lead to ocular damage and complete visual loss. Noninfectious etiologies for uveitis are the most common in the U.S.1 The estimated incidence of uveitis ranges from 25–52 per 100,000 in adults and five per 100,000 in children. The…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences